FINWIRES · TerminalLIVE
FINWIRES

美國天然氣市場最新消息:供應充足,短期需求疲軟,期貨價格持平

-- 週三,美國天然氣期貨價格持平,強勁的供應和疲軟的近期需求繼續對價格構成壓力。 近月亨利樞紐天然氣合約和連續基準價格上漲0.04%,至每百萬英熱單位2.60美元。 隨著中東衝突降級,美國總統川普暗示將在未來幾週內迅速解決衝突,歐洲天然氣期貨價格持續下跌。 然而,對美國市場而言,國內因素才是主要驅動力。根據NRG能源公司的數據顯示,過去幾天美國天然氣產量強勁,平均日產量約為1072億立方英尺,而由於供暖需求下降,居民和商業需求減少了50億立方英尺/日。 由於全美各地的液化天然氣設施都在滿載運轉,美國天然氣市場在很大程度上不受中東衝突的影響。 根據 Investing.com 彙編的數據顯示,市場預期美國能源資訊署 (EIA) 將於週四發布的周報將顯示天然氣庫存淨增 550 億立方英尺 (Bcf),高於上週的 500 億立方英尺。 天氣預報仍然悲觀,根據美國國家氣象局預測,4 月 22 日至 28 日期間,美國大部分地區的氣溫預計將高於正常水平,這將抑制天然氣需求。

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

$KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

$BOM:524715$NSE:SUNPHARMA